AUS
NZ
UK
CA
USA
IND
Highlights
- Amplia Therapeutics partners with Next&Bio to evaluate the impact of FAK inhibitors on pancreatic cancer.
- The study explores potential synergy between Amplia’s AMP945 and emerging kRas inhibitors.
- Next&Bio uses advanced patient-derived models to simulate the tumor environment.
The healthcare sector has seen a significant collaboration between Amplia Therapeutics (ASX:ATX) and Next&Bio, a subsidiary of Hk Kolmar Holdings. This partnership focuses on advancing preclinical research in pancreatic cancer treatment, leveraging their combined expertise to explore new therapeutic options. Pancreatic cancer is a challenging area of oncology, often associated with oncogenic mutations like kRas.
Amplia Therapeutics brings its proprietary focal adhesion kinase (FAK) inhibitors to the collaboration, aiming to test their efficacy when combined with kRas inhibitors. The research will use Next&Bio’s advanced drug screening technology, which utilizes patient-derived cancer cells cultivated under conditions closely mimicking the tumor environment. This approach allows a precise evaluation of the potential effectiveness of experimental treatments.
At the forefront of this collaboration is Amplia’s narmafotinib (AMP945), a selective and potent FAK inhibitor. AMP945 is currently undergoing Phase 2a clinical trials to assess its safety and efficacy in combination with gemcitabine and Abraxane® for pancreatic cancer. The preclinical work with Next&Bio will further examine how AMP945 performs against pancreatic cancer cells harboring kRas mutations and its compatibility with kRas inhibitors, a promising class of drugs under development.
Next&Bio’s models are uniquely designed to replicate the complex tumor environment, which is crucial for testing experimental therapies. These systems enable researchers to measure how patient-derived cells respond to drug candidates like AMP945, especially in cases involving mutations such as kRas.
The collaboration is set to explore potential synergistic effects between AMP945 and kRas inhibitors. If successful, it could provide valuable insights into combination therapies that enhance treatment options for pancreatic cancer patients. The focus on combination therapies highlights the importance of collaborative research in addressing unmet medical needs.
Amplia Therapeutics’ CEO, Dr. John Burns, emphasized the significance of testing FAK inhibitors in advanced cell systems, which can open doors to new commercial applications for combination treatments in oncology. By leveraging innovative screening techniques and Amplia’s advanced drug candidates, the partnership seeks to create a foundation for future therapeutic breakthroughs in pancreatic cancer.
This collaboration reflects a growing trend in the biopharmaceutical industry to explore combination therapies as a way to tackle complex diseases, bringing hope for improved outcomes in challenging cancers like pancreatic.
